Congress and Continuing Medical Education: Last Chance for Self-Policing
This article was originally published in RPM Report
Senate Finance Committee minority staff investigator Paul Thacker has been a leading figure behind the effort to make public the recipients of pharma funding and grants. Here are his thoughts from a recent conference on the future of industry funded CME.
You may also be interested in...
Let The Sunshine In: Health Care Reform Law Mandates Public Disclosure of Financial Ties Between Industry and Physicians
The "physician payments sunshine" provisions of the recently enacted health care reform legislation may chill relations between industry and physicians. They also are likely to impose significant costs on drug and device manufacturers.
It was fitting that this year's TCT conference included a session on physician/industry conflicts of interest since this has been a hot topic recently in the press, and because TCT is probably the most industry-focused of all the major clinical conferences. Not surprisingly, the panel of physicians raised more questions than answers about both individual and institutional conflicts and how they should be handled.
Pharma's $2 billion in payouts since 2000 to settle claims of fraudulent Medicaid-related marketing and pricing practices has left the industry in flux, as it seeks to determine the kinds of packages and programs that will pass government muster. It appears that the strength of many current and presumed future fraud cases will be based on establishing a company's reasonable foreknowledge of the activities of its customers, with the argument even extended to gray areas including improper encouragement of off-label drug usage and the development of data to support those uses--issues that will affect device companies at least as much as Pharma.